ArticleBreast care (Basel, Switzerland)2025
Distinct Immune Landscape and Gene Expression Profiles in Breast Cancer: Young versus Non-Young Patients.
Article in Breast care (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- EBCC-15 manifesto: Removing age-related barriers to improve equity in breast cancer care.Breast (Edinburgh, Scotland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer remains a prevalent malignancy worldwide, particularly affecting younger women more aggressively. Significant differences in clinical and biological characteristics exist between breast cancer with young patients (BCY) and breast cancer with non-young patients (BCNY). However, the role of the immune microenvironment in these differences is not fully understood. Methods: Data from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) database were analyzed to compare tumor-infiltrating immune cells (TIICs) and gene expression between BCY and BCNY. The CIBERSORT algorithm was used to estimate the relative abundance of 22 immune cell types, and differentially expressed genes were identified using the "limma" package in R. Results: The BCY group had a higher prevalence of M0 macrophages and activated dendritic cells, while the BCNY group exhibited greater infiltration of CD4 memory T cells, M2 macrophages, and neutrophils. Differential gene expression analysis identified 11 significantly expressed genes between the groups, with genes such as FDCSP and GABRP upregulated in the BCY group. GSEA revealed that pro-inflammatory pathways, such as cytokine-cytokine receptor interaction, were enriched in the BCY group, while pathways related to metabolism and extracellular matrix interactions were enriched in the BCNY group. Kaplan-Meier analysis demonstrated that high expression of certain genes, such as NAT1, CA12, and SRARP, was associated with better relapse-free survival. Conclusion: This study reveals significant differences in immune cell infiltration, gene expression, and pathways between BCY and BCNY, providing insights into the aggressive tumor biology that may explain the poorer prognosis of BCY.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.